PHARMACEUTICAL OR NUTRITIONAL COMPOSITIONS CONTAINING GALACTOSIDASE, AND THEIR USE
The present disclosure relates to pharmaceutical or nutritional compositions containing α-galactosidase and β-galactosidase and their use in the prevention and/or treatment of gastroesophageal reflux disease; in particular the present disclosure related to pharmaceutical or nutritional compositions.
1 . A pharmaceutical or nutritional composition containing α-galactosidase and β-galactosidase and at least one pharmaceutically acceptable excipient or carrier.
2 . The pharmaceutical or nutritional composition according to claim 1 , wherein the content of α-galactosidase ranges from 75 to 2400 GalU and the content of β-galactosidase ranges from 2500 to 12500 LactU in the form of a dosage unit.
3 . The pharmaceutical or nutritional composition according to claim 1 , wherein the composition is formulated for oral administration.
4 . The pharmaceutical or nutritional composition according to claim 3 , wherein the composition is formulated in a solid form selected from powders, granules, tablets, pills and capsules.
5 . The pharmaceutical or nutritional composition according to claim 3 , wherein the composition is formulated in a liquid form selected from emulsions, syrups, elixirs, suspensions and solutions.
6 . The pharmaceutical or nutritional composition according to claim 1 , wherein the content of α-galactosidase ranges from 300 to 1200 GalU and the content of β-galactosidase ranges from 3500 to 11000 LactU in the form of a dosage unit.
7 . The pharmaceutical or nutritional composition according to claim 1 , wherein the amount of α-galactosidase is 30 mg and the amount of β-galactosidase is 69 mg.
8 . The pharmaceutical or nutritional composition according to claim 1 , wherein the content of α-galactosidase is 10000 GalU/g and the content of β-galactosidase is 65000 LactU/g.